Skip to Content

Tag: Sleep Apnea


Also Noted

Researchers take different approach to adherence to CPAP therapy 

December 6, 2022HME News Staff

CHICAGO – Researchers at the University of Chicago and Northwestern University are testing an app with a new adherence metric: the percentage of time a user wears their CPAP device relative to their time spent sleeping. “Sleep apnea can be effectively treated only when CPAP is used during the entire time spent in bed sleeping,” said Esra Tasali, MD, director of the UChicago Sleep Center and senior author of an initial study on the app published Dec. 5 in the Journal of Medical...

CPAP Compliance, Sleep Apnea


Read Full Articlered right arrow icon

Vendors

Primasun debuts ‘efficient, equitable solution’ 

November 14, 2022HME News Staff

LAS VEGAS – Primasun, a solution to address complex sleep disorders that was formed as a joint venture between ResMed and Verily, launched at the HLTH 2022 event on Nov. 13.  Through its preventative care model, Primasun works with employers and health care providers to identify populations at risk and connects patients to certified sleep physicians who guide them from diagnosis to treatment in a matter of weeks.  "Sleep is the foundation of physical and mental health, and at...

Primasun, ResMed, Sleep Apnea, Verily


Read Full Articlered right arrow icon

Also Noted

CPAPSupplies.com, Resonea partner to offer OSA screening, equipment

November 9, 2022HME News Staff

ARDEN, N.C., and SCOTTSDALE, Ariz. – CPAPSupplies.com and Resonea, a medtech company focused on sleep health, have partnered to offer OSA screening services and equipment. “We strive to give our customers top-rated products from trusted brands at competitive prices and exceptional care,” said Lauren Bennet, vice president of sales operations at CPAPSupplies.com. “Being able to offer OSA screening to our clients that they can do from their smartphone is a game changer for us....

CPAPSupplies.com, Resonea, Sleep Apnea


Read Full Articlered right arrow icon

Mick Farrell

Vendors

ResMed’s strategy pays off

October 28, 2022Liz Beaulieu, Editor

  SAN DIEGO – ResMed’s card-to-cloud CPAP device, launched earlier in 2022, provided “meaningful growth” for the first quarter of the company’s fiscal year 2023, said CEO Mick Farrell.  The AirSense 10 card-to-cloud device is one of the company’s workarounds for pumping product into the market amid a competitor’s recall that has significantly increased demand and supply chain challenges that have limited the supply of semiconductor chips,...

CPAP recall, ResMed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

AASM to pilot sleep scoring program

September 1, 2022HME News Staff

DARIEN, Ill. – The American Academy of Sleep Medicine has created a two-year pilot program to evaluate and certify software that uses auto-scoring functionality to score polysomnograms. The AI/Autoscoring Certification Program will independently verify the performance of auto-scoring systems. To obtain certification, the software must demonstrate accuracy that is equivalent or better than manual scoring. The pilot program is limited to sleep stage scoring. “Artificial intelligence technology...

American Academy of Sleep Medicine, Sleep Apnea


Read Full Articlered right arrow icon

SleepRes hires former Philips engineer 

Also Noted

SleepRes hires former Philips engineer 

July 22, 2022HME News Staff

NASHVILLE, Tenn. - SleepRes, developer of the V̇-Com, has announced Bernard Hete, PhD, as its chief technology officer to oversee future research and development. He was a senior engineer at Philips Respironics for 30 years. “Bernie [Dr. Hete] was always the smartest guy in the room, who always kept our ideas at Respironics to the laws of physics,” said Eugene Scarberry, a retired senior engineer at Philips who got the first FDA approval for CPAP back in 1985. “I have known Bernie...

accessory, CPAP Device, Sleep Apnea, SleepRes, V-Com


Read Full Articlered right arrow icon

Also Noted

RemSleep receives OTCQB status

July 13, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings has received approval to be uplisted to OTCQB status with otcmarkets.com. “This is a great milestone for RemSleep and our shareholders,” said Tom Wood, CEO. “We could not be more excited for where we are currently positioned and the trajectory of where we are going. Uplisting to OTCQB status provides next level accountability from us as a company with higher reporting standards and more comprehensive compliance requirements.” RemSleep...

RemSleep, Sleep Apnea


Read Full Articlered right arrow icon

Business Development

Sleep industry grapples with shortages

May 26, 2022John Andrews

While supply chain delays have been a major choke point for the U.S. economy over the past year, the recall of Philips Respironics’ flow generators and masks has compounded the obstruction in the sleep therapy market. The ensuing vacuum created by the recall caused a ripple effect throughout the marketplace, causing various suppliers to scramble for ways to cover the shortage.  At this point, suppliers are still frustrated by a hardscrabble supply line, but remain hopeful that product...

CPAP, CPAP recall, Philips Recall, Sleep Apnea, supply chain challenges


Read Full Articlered right arrow icon

Vendors

Sleep study questions adherence requirements 

May 19, 2022HME News Staff

SAN DIEGO – Sleep apnea sufferers can gain health benefits from PAP treatment in as little as two hours per night, according to a study led by ResMed and presented at the American Thoracic Society’s annual international conference.  Researchers found:  The minimum PAP usage threshold for benefit was two to three hours per night (up to 50% lower than the four hours required by CMS and many private insurers to prove adherence);  Benefits begin at two hours of nightly...

Adherence, PAP treatment, ResMed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Apnimed secures funding for OSA treatment

May 5, 2022HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon